Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.

Barry Mirtsching, Veena Charu, Saroj Vadhan-Raj, Alan B. Colowick, Gregory Rossi, Dianne Tomita, William P. McGuire

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 microg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by pooling data from three darbepoetin alfa clinical studies. All studies enrolled anemic (hemoglobin < or = 11.0 g/dL) patients receiving multicycle chemotherapy. Open-label study drug was administered by subcutaneous injection. Hemoglobin concentrations, red blood cell transfusion requirements, and standard safety parameters were evaluated. Of 260 patients who received darbepoetin alfa at 3.0 microg/kg every 2 weeks and 115 patients who received rHuEPO three times weekly or once weekly, hematopoietic response (change in hemoglobin from baseline of > or = 2 g/dL or hemoglobin concentration of > or = 12 g/dL) was achieved in 71% (95% confidence interval [CI] = 65%-78%) of patients who received darbepoetin alfa every 2 weeks, comparable to the response in patients who received rHuEPO (71%; 95% CI = 61%-81%). The mean increase in hemoglobin concentration over 13 weeks was also similar: 1.48 g/dL (95% CI = 1.28-1.68 g/dL) for darbepoetin alfa and 1.31 g/dL (95% CI = 0.97-1.64 g/dL) for rHuEPO. The proportion of patients in the darbepoetin alfa group requiring transfusions was lower (7%; 95% CI = 4%-11%) than that in the rHuEPO group (14%; 95% CI = 8%-22%). Darbepoetin alfa every 2 weeks was well tolerated with a safety profile comparable to that of rHuEPO. In conclusion, darbepoetin alfa at a dose of 3.0 microg/kg given every 2 weeks safely increases hemoglobin concentration to the same extent as rHuEPO.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalOncology (Williston Park, N.Y.)
Volume16
Issue number10 Suppl 11
StatePublished - Oct 2002

Fingerprint

Erythropoietin
Anemia
Drug Therapy
Confidence Intervals
Hemoglobins
Safety
Darbepoetin alfa
Meta-Analysis

ASJC Scopus subject areas

  • Oncology

Cite this

Mirtsching, B., Charu, V., Vadhan-Raj, S., Colowick, A. B., Rossi, G., Tomita, D., & McGuire, W. P. (2002). Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Oncology (Williston Park, N.Y.), 16(10 Suppl 11), 31-36.

Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. / Mirtsching, Barry; Charu, Veena; Vadhan-Raj, Saroj; Colowick, Alan B.; Rossi, Gregory; Tomita, Dianne; McGuire, William P.

In: Oncology (Williston Park, N.Y.), Vol. 16, No. 10 Suppl 11, 10.2002, p. 31-36.

Research output: Contribution to journalArticle

Mirtsching, B, Charu, V, Vadhan-Raj, S, Colowick, AB, Rossi, G, Tomita, D & McGuire, WP 2002, 'Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.', Oncology (Williston Park, N.Y.), vol. 16, no. 10 Suppl 11, pp. 31-36.
Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D et al. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Oncology (Williston Park, N.Y.). 2002 Oct;16(10 Suppl 11):31-36.
Mirtsching, Barry ; Charu, Veena ; Vadhan-Raj, Saroj ; Colowick, Alan B. ; Rossi, Gregory ; Tomita, Dianne ; McGuire, William P. / Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. In: Oncology (Williston Park, N.Y.). 2002 ; Vol. 16, No. 10 Suppl 11. pp. 31-36.
@article{8c804f44556440c4b6475f173bd541fd,
title = "Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.",
abstract = "The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 microg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by pooling data from three darbepoetin alfa clinical studies. All studies enrolled anemic (hemoglobin < or = 11.0 g/dL) patients receiving multicycle chemotherapy. Open-label study drug was administered by subcutaneous injection. Hemoglobin concentrations, red blood cell transfusion requirements, and standard safety parameters were evaluated. Of 260 patients who received darbepoetin alfa at 3.0 microg/kg every 2 weeks and 115 patients who received rHuEPO three times weekly or once weekly, hematopoietic response (change in hemoglobin from baseline of > or = 2 g/dL or hemoglobin concentration of > or = 12 g/dL) was achieved in 71{\%} (95{\%} confidence interval [CI] = 65{\%}-78{\%}) of patients who received darbepoetin alfa every 2 weeks, comparable to the response in patients who received rHuEPO (71{\%}; 95{\%} CI = 61{\%}-81{\%}). The mean increase in hemoglobin concentration over 13 weeks was also similar: 1.48 g/dL (95{\%} CI = 1.28-1.68 g/dL) for darbepoetin alfa and 1.31 g/dL (95{\%} CI = 0.97-1.64 g/dL) for rHuEPO. The proportion of patients in the darbepoetin alfa group requiring transfusions was lower (7{\%}; 95{\%} CI = 4{\%}-11{\%}) than that in the rHuEPO group (14{\%}; 95{\%} CI = 8{\%}-22{\%}). Darbepoetin alfa every 2 weeks was well tolerated with a safety profile comparable to that of rHuEPO. In conclusion, darbepoetin alfa at a dose of 3.0 microg/kg given every 2 weeks safely increases hemoglobin concentration to the same extent as rHuEPO.",
author = "Barry Mirtsching and Veena Charu and Saroj Vadhan-Raj and Colowick, {Alan B.} and Gregory Rossi and Dianne Tomita and McGuire, {William P.}",
year = "2002",
month = "10",
language = "English (US)",
volume = "16",
pages = "31--36",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10 Suppl 11",

}

TY - JOUR

T1 - Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.

AU - Mirtsching, Barry

AU - Charu, Veena

AU - Vadhan-Raj, Saroj

AU - Colowick, Alan B.

AU - Rossi, Gregory

AU - Tomita, Dianne

AU - McGuire, William P.

PY - 2002/10

Y1 - 2002/10

N2 - The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 microg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by pooling data from three darbepoetin alfa clinical studies. All studies enrolled anemic (hemoglobin < or = 11.0 g/dL) patients receiving multicycle chemotherapy. Open-label study drug was administered by subcutaneous injection. Hemoglobin concentrations, red blood cell transfusion requirements, and standard safety parameters were evaluated. Of 260 patients who received darbepoetin alfa at 3.0 microg/kg every 2 weeks and 115 patients who received rHuEPO three times weekly or once weekly, hematopoietic response (change in hemoglobin from baseline of > or = 2 g/dL or hemoglobin concentration of > or = 12 g/dL) was achieved in 71% (95% confidence interval [CI] = 65%-78%) of patients who received darbepoetin alfa every 2 weeks, comparable to the response in patients who received rHuEPO (71%; 95% CI = 61%-81%). The mean increase in hemoglobin concentration over 13 weeks was also similar: 1.48 g/dL (95% CI = 1.28-1.68 g/dL) for darbepoetin alfa and 1.31 g/dL (95% CI = 0.97-1.64 g/dL) for rHuEPO. The proportion of patients in the darbepoetin alfa group requiring transfusions was lower (7%; 95% CI = 4%-11%) than that in the rHuEPO group (14%; 95% CI = 8%-22%). Darbepoetin alfa every 2 weeks was well tolerated with a safety profile comparable to that of rHuEPO. In conclusion, darbepoetin alfa at a dose of 3.0 microg/kg given every 2 weeks safely increases hemoglobin concentration to the same extent as rHuEPO.

AB - The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 microg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by pooling data from three darbepoetin alfa clinical studies. All studies enrolled anemic (hemoglobin < or = 11.0 g/dL) patients receiving multicycle chemotherapy. Open-label study drug was administered by subcutaneous injection. Hemoglobin concentrations, red blood cell transfusion requirements, and standard safety parameters were evaluated. Of 260 patients who received darbepoetin alfa at 3.0 microg/kg every 2 weeks and 115 patients who received rHuEPO three times weekly or once weekly, hematopoietic response (change in hemoglobin from baseline of > or = 2 g/dL or hemoglobin concentration of > or = 12 g/dL) was achieved in 71% (95% confidence interval [CI] = 65%-78%) of patients who received darbepoetin alfa every 2 weeks, comparable to the response in patients who received rHuEPO (71%; 95% CI = 61%-81%). The mean increase in hemoglobin concentration over 13 weeks was also similar: 1.48 g/dL (95% CI = 1.28-1.68 g/dL) for darbepoetin alfa and 1.31 g/dL (95% CI = 0.97-1.64 g/dL) for rHuEPO. The proportion of patients in the darbepoetin alfa group requiring transfusions was lower (7%; 95% CI = 4%-11%) than that in the rHuEPO group (14%; 95% CI = 8%-22%). Darbepoetin alfa every 2 weeks was well tolerated with a safety profile comparable to that of rHuEPO. In conclusion, darbepoetin alfa at a dose of 3.0 microg/kg given every 2 weeks safely increases hemoglobin concentration to the same extent as rHuEPO.

UR - http://www.scopus.com/inward/record.url?scp=0036779996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036779996&partnerID=8YFLogxK

M3 - Article

C2 - 12435171

AN - SCOPUS:0036779996

VL - 16

SP - 31

EP - 36

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 10 Suppl 11

ER -